Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Sep;57(5):362-5.
doi: 10.4103/0019-5154.100476.

Dose related efficacy of gabapentin in acute herpetic neuralgia among geriatric patients

Sanjay Kumar Kanodia  1 , Amoolya K Seth, Anand Mohan Dixit
Affiliations

Dose related efficacy of gabapentin in acute herpetic neuralgia among geriatric patients

Sanjay Kumar Kanodia et al. Indian J Dermatol. 2012 Sep.

Abstract

Background: Herpes zoster is an intractable painful condition, more severe in elderly patients. The pain during the first 30 days of onset is known as Acute Herpetic Neuralgia. Multiple treatments using non-steroidal anti-inflammatory drugs (NSAIDs), opioids, and tricyclic anti-depressants are available, but their side effects limit their use in geriatric patients. Gabapentin is also used in chronic neuropathic pain; however, its role in acute herpetic neuralgia is less explored.

Aim: This study was aimed to determine dose related efficacy and safety of gabapentin in reducing pain of acute herpetic neuralgia in geriatric patients.

Materials and methods: In this placebo-controlled, four-week trial including 56 subjects, 42 patients received gabapentin in the dosage of 300 mg (n=15), 600 mg (n=14), and 900 mg(n=13) per day in divided doses and 14 patients received placebo within 72 hours of onset of herpes zoster.

Results: Subjects receiving gabapentin had a statistically significant reduction (P<0.0001) in visual analog scale (VAS) score as compared to placebo, emphasizing the efficacy of gabapentin in the treatment of acute pain associated with herpes zoster on each assessment (weeks 1, 2, 3, and 4). Gabapentin in doses of 600 mg/day and 900 mg/day was better than 300 mg/day in each visit. However, no difference was observed between gabapentin 600 mg/day and 900 mg/day group at any point of time (P>0.05).

Conclusion: The results of this study show that gabapentin is effective in acute herpetic neuralgia in different doses with 600 mg/day being the more appropriate dose in terms of safety and efficacy.

Keywords: Acute herpetic neuralgia; gabapentin; geriatric patients; herpes zoster; post herpetic neuralgia; visual analogue scale.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: Nil.

References

    1. Rogers RS, 3rd, Tindall JP. Geriatric herpes zoster. J Am Geriatr Soc. 1971;19:495–504. - PubMed
    1. Wood M. How can the burden of zoster-associated pain be reduced? Recommendations from the IHMF Workshop, Washington, D.C. Worthing United Kingdom: PPS Europe; 1993. May 15, Understanding zoster-associated pain; pp. 3–11.
    1. Dworkin RH, Johnson RW, Breuer J, Gnann JW, Levin MJ. Recommendations for the management of herpes zoster. Clin Infect Dis. 2007;44(Suppl 1):S1–26. - PubMed
    1. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: A randomized controlled trial. JAMA. 1998;280:1837–42. - PubMed
    1. Rice AS, Maton S. Gabapentin in postherpetic neuralgia: A randomised, double blind, placebo controlled study. Pain. 2001;94:215–24. - PubMed